Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...

Adding Kisqali (ribociclib) to a nonsteroidal aromatase inhibitor helped patients with hormone receptor–positive, HER2-negative early breast cancer live longer without their disease returning, ...

Researchers appear to have found a solution for breast cancer patients who do not respond well enough to the common treatment ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

She emphasized that while elacestrant has properties similar to other agents, imlunestrant is closer to a “pure” ER ...

Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, ...

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo ...

BUFFALO, N.Y. — One class of drugs that has shown promise in treating diseases ranging from lung cancer to COVID-19 are targeted covalent inhibitors (TCIs). These small molecule drugs form covalent ...

ABSTRACT: Objective: This study investigates the effects of tamoxifen, a selective estrogen receptor modulator, and letrozole, an aromatase inhibitor, on the endometrium in a rat model. It further ...